Drug intelligence / Profile preview

hydroxychloroquine + methotrexate + yisaipu

Development stage: Phase 4
Lead developer: 3S Guojian Pharmaceutical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous, Intramuscular

Overview

This is a combination therapy consisting of three medications used for the treatment of autoimmune conditions, particularly rheumatoid arthritis. The combination includes: - **Hydroxychloroquine**: An antimalarial drug that also has anti-inflammatory properties - **Methotrexate**: A disease-modifying antirheumatic drug (DMARD) that suppresses the immune system - **Yisaipu (etanercept biosimilar)**: A recombinant human tumor necrosis factor-α receptor II:IgG-Fc fusion protein that inhibits TNF-α, a key inflammatory mediator in autoimmune diseases

Targets

DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on hydroxychloroquine + methotrexate + yisaipu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + methotrexate + yisaipu.